NO20021407D0 - Biphenyl derivatives used as NHE-3 inhibitors - Google Patents
Biphenyl derivatives used as NHE-3 inhibitorsInfo
- Publication number
- NO20021407D0 NO20021407D0 NO20021407A NO20021407A NO20021407D0 NO 20021407 D0 NO20021407 D0 NO 20021407D0 NO 20021407 A NO20021407 A NO 20021407A NO 20021407 A NO20021407 A NO 20021407A NO 20021407 D0 NO20021407 D0 NO 20021407D0
- Authority
- NO
- Norway
- Prior art keywords
- nhe
- inhibitors
- derivatives used
- biphenyl derivatives
- biphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19945302A DE19945302A1 (en) | 1999-09-22 | 1999-09-22 | Biphenyl derivatives as NHE-3 inhibitors |
PCT/EP2000/008616 WO2001021582A1 (en) | 1999-09-22 | 2000-09-04 | Biphenyl derivatives used as nhe-3 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20021407L NO20021407L (en) | 2002-03-21 |
NO20021407D0 true NO20021407D0 (en) | 2002-03-21 |
Family
ID=7922831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021407A NO20021407D0 (en) | 1999-09-22 | 2002-03-21 | Biphenyl derivatives used as NHE-3 inhibitors |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1214291A1 (en) |
JP (1) | JP2004500338A (en) |
KR (1) | KR20020033818A (en) |
CN (1) | CN1555356A (en) |
AU (1) | AU7649700A (en) |
BR (1) | BR0014199A (en) |
CA (1) | CA2387529A1 (en) |
CZ (1) | CZ2002815A3 (en) |
DE (1) | DE19945302A1 (en) |
HU (1) | HUP0202891A3 (en) |
MX (1) | MXPA02003087A (en) |
NO (1) | NO20021407D0 (en) |
PL (1) | PL355097A1 (en) |
SK (1) | SK3342002A3 (en) |
WO (1) | WO2001021582A1 (en) |
ZA (1) | ZA200203095B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10163239A1 (en) * | 2001-12-21 | 2003-07-10 | Aventis Pharma Gmbh | Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them |
US7049333B2 (en) | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
DE10304374A1 (en) | 2003-02-04 | 2004-08-05 | Aventis Pharma Deutschland Gmbh | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic agent and medicament containing them |
US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
DE10341240A1 (en) | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituted thienoimidazoles, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
DE102005001411A1 (en) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them |
EP2170872B1 (en) | 2007-06-28 | 2010-09-01 | Sanofi-Aventis U.S. LLC | Process for the preparation of the n-(2-chloro-4-methyl-3-thienyl)-1h- benzimidazol-2-amine hydrochloride and intermediates thereof |
JP5745406B2 (en) | 2008-09-02 | 2015-07-08 | サノフイ | Substituted aminoindanes and analogs thereof, and pharmaceutical uses thereof |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
ES2657938T3 (en) | 2008-12-31 | 2018-03-07 | Ardelyx, Inc. | Compounds and methods to inhibit NHE-mediated anti-port in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
PL2695881T3 (en) | 2011-03-15 | 2016-11-30 | Guanidine compound | |
CN103012200B (en) * | 2011-09-20 | 2014-12-17 | 北京大学 | Compound with beta-secretase inhibition function, preparation method and applications thereof |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
CN104902930A (en) | 2012-08-21 | 2015-09-09 | 阿德利克斯公司 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
ES2735992T3 (en) | 2013-04-12 | 2019-12-23 | Ardelyx Inc | NHE3 binding compounds and procedures to inhibit phosphate transport |
LT3173408T (en) | 2014-07-25 | 2018-12-27 | Taisho Pharmaceutical Co., Ltd. | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl |
EP3565808A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
EA201991676A1 (en) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | NHE-MEDIATED ANTI-PORT INHIBITORS |
BR112020002322A2 (en) | 2017-08-04 | 2020-09-01 | Ardelyx, Inc. | glycyrrhetinic acid derivatives for the treatment of hyperkalaemia |
AU2020218255A1 (en) | 2019-02-07 | 2021-09-09 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
JP2022533251A (en) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | Combinations to lower serum phosphate in patients |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19548812A1 (en) * | 1995-12-27 | 1997-07-03 | Hoechst Ag | Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation |
DE19622222A1 (en) * | 1996-06-03 | 1997-12-04 | Hoechst Ag | Use of sodium=proton exchange inhibitor |
DE19737224A1 (en) * | 1997-08-27 | 1999-03-18 | Hoechst Marion Roussel De Gmbh | Pharmaceutical preparation for cardiovascular treatment |
DE19819548A1 (en) * | 1998-04-30 | 1999-11-04 | Merck Patent Gmbh | Biphenyl derivatives |
-
1999
- 1999-09-22 DE DE19945302A patent/DE19945302A1/en not_active Withdrawn
-
2000
- 2000-09-04 WO PCT/EP2000/008616 patent/WO2001021582A1/en not_active Application Discontinuation
- 2000-09-04 CN CNA008131600A patent/CN1555356A/en active Pending
- 2000-09-04 MX MXPA02003087A patent/MXPA02003087A/en unknown
- 2000-09-04 EP EP00965915A patent/EP1214291A1/en not_active Withdrawn
- 2000-09-04 CA CA002387529A patent/CA2387529A1/en not_active Abandoned
- 2000-09-04 JP JP2001524962A patent/JP2004500338A/en active Pending
- 2000-09-04 SK SK334-2002A patent/SK3342002A3/en not_active Application Discontinuation
- 2000-09-04 KR KR1020027003735A patent/KR20020033818A/en not_active Application Discontinuation
- 2000-09-04 PL PL00355097A patent/PL355097A1/en unknown
- 2000-09-04 HU HU0202891A patent/HUP0202891A3/en unknown
- 2000-09-04 BR BR0014199-2A patent/BR0014199A/en not_active IP Right Cessation
- 2000-09-04 CZ CZ2002815A patent/CZ2002815A3/en unknown
- 2000-09-04 AU AU76497/00A patent/AU7649700A/en not_active Abandoned
-
2002
- 2002-03-21 NO NO20021407A patent/NO20021407D0/en unknown
- 2002-04-18 ZA ZA200203095A patent/ZA200203095B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20021407L (en) | 2002-03-21 |
MXPA02003087A (en) | 2003-08-20 |
CN1555356A (en) | 2004-12-15 |
JP2004500338A (en) | 2004-01-08 |
EP1214291A1 (en) | 2002-06-19 |
BR0014199A (en) | 2002-05-21 |
ZA200203095B (en) | 2003-09-23 |
WO2001021582A1 (en) | 2001-03-29 |
KR20020033818A (en) | 2002-05-07 |
HUP0202891A3 (en) | 2003-11-28 |
CZ2002815A3 (en) | 2002-08-14 |
DE19945302A1 (en) | 2001-03-29 |
SK3342002A3 (en) | 2002-07-02 |
PL355097A1 (en) | 2004-03-22 |
HUP0202891A2 (en) | 2003-02-28 |
AU7649700A (en) | 2001-04-24 |
CA2387529A1 (en) | 2001-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1244647T3 (en) | Quinzoline derivatives as VIGF inhibitors | |
DK2253620T3 (en) | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN-TYROSINKINASE INHIBITORS | |
NO20021407L (en) | Biphenyl derivatives used as NHE-3 inhibitors | |
NO20021239D0 (en) | Pteridinones as kinase inhibitors | |
NO20024997D0 (en) | 2-guanidino-4-arylquinazolines as NHE-3 inhibitors | |
NO20030055L (en) | Colchinol derivatives as angiogenesis inhibitors | |
NO20023828L (en) | Pyrimidin-4-one derivatives as LDL-PLA2 inhibitors | |
NO20030867L (en) | Hydroxam derivatives useful as deacetylase inhibitors | |
NO20014483L (en) | Amine derivatives as protease inhibitors | |
NO992725L (en) | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | |
NO20014412L (en) | Compounds useful as anti-inflammatory agents | |
NO20015065D0 (en) | Pyrazolobenzodiazepines as CDK2 inhibitors | |
NO20031006L (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibiting cell proliferation | |
ATE524441T1 (en) | VLA-4 INHIBITORS | |
NO20033618D0 (en) | Phthalayinone-piperidino derivatives as PDE-4 inhibitors | |
DK1097127T3 (en) | Diacylhydrazine derivatives as integrin inhibitors | |
NO20022558D0 (en) | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor | |
NO20016201D0 (en) | Tienopyrimidines as phosphodiesterase inhibitors | |
NO20021959D0 (en) | Tetrahydrotiopyranephthalazinone derivatives as PDE4 inhibitors | |
NO991994L (en) | Substituted 4-biphenyl-4-hydroxy acid derivatives as matrix metalloprotease inhibitors | |
NO20023001D0 (en) | Substituted piperazine derivatives as MTP inhibitors | |
DE60009260D1 (en) | THIOPYRANDERIVATE AS MMP INHIBITORS | |
NO20011654L (en) | Benzamide derivatives as thrombin inhibitors | |
NO20010400L (en) | Isoquinolines as urokinase inhibitors | |
NO20020592D0 (en) | Fluorine derivatives as integrin inhibitors |